Clinical trial
A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)
NCT03216226 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)
- Lead sponsor
- Zealand Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 28, 2017
- Completion date
- February 13, 2018
- Enrollment
- 112 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.